iBio, Inc. and Caliber Biotherapeutics have entered a license and collaboration agreement for the development and production of recombinant plant-based biopharmaceuticals using iBio’s iBioLaunch technology and Caliber’s plant-based manufacturing capabilities.   The companies will use their combined capabilities for their respective portfolios, starting with an undisclosed monoclonal antibody for oncology indications, and will also make these capabilities available to third parties th...